The Europe glucose monitoring devices market is expected to grow from US$ 5,248.87 million in 2022 to US$ 12,118.27 million by 2030. It is estimated to grow at a CAGR of 11.0% from 2022 to 2030.
Based on type, the Europe glucose monitoring devices market is segmented into continuous glucose monitoring devices and self-glucose monitoring devices. The self-glucose monitoring devices segment held a larger share of the Europe glucose monitoring devices market in 2022.
Based on application, the Europe glucose monitoring devices market is segmented into type 1 diabetes and type 2 diabetes. The type 2 diabetes segment held a larger share of the Europe glucose monitoring devices market in 2022.
Based on testing site, the Europe glucose monitoring devices market is segmented into fingertip testing and alternate site testing. The fingertip testing segment held a larger share of the Europe glucose monitoring devices market in 2022.
Based on end user, the Europe glucose monitoring devices market is segmented into healthcare setting and self/homecare. The self/homecare segment held a larger share of the Europe glucose monitoring devices market in 2022.
Based on country, the Europe glucose monitoring devices market is segmented int o the Germany, UK, France, Italy, Spain, and Rest of Europe. Germany dominated the Europe glucose monitoring devices market in 2022.
B. Braun SE, F. Hoffmann-La Roche Ltd, Medtronic Plc, Abbott Laboratories, Ypsomed Holding AG, Senseonics Holdings Inc, Nipro Corp, GE HealthCare Technologies Inc, and Terumo Corp are some of the leading companies operating in the Europe glucose monitoring devices market.
Growing Medical Tourism in Developing Countries Fuel Europe Glucose Monitoring Devices Market
The emerging markets in developing countries are the major factor that gives the major players a better opportunity to expand their business. These are a major reason for the market growth during the forecast period. Most market players focus on emerging markets due to the prevalence of diabetes and the increasing popularity of glucose monitoring devices in the region. In India, medical science has progressed rapidly over the past few decades. Several international patients visit India in the pursuit of incredibly affordable medical care. Moreover, Poland has slowly become a favorite medical tourism destination in Europe. For instance, in Poland, medical treatment costs are often lower by 60-80% compared to the same benefits in the rest of the EU countries. The major reason for the growth of tourism is Poland's recognition and acceptance of the European Union. The rising medical tourism in emerging nations such as Poland is anticipated to provide significant growth opportunities to the players operating in the market during the forecast period.Europe Glucose Monitoring Devices Market Overview
The Europe glucose monitoring devices market has been segmented into the Germany, France, UK, Italy, Spain, Rest of Europe. The market growth in this region is attributed to the rising awareness of the diabetes diagnosis, increasing ageing population, and technological advancements in glucose monitoring thereby dominating the overall market growth.Europe Glucose Monitoring Devices Market Revenue and Forecast to 2030 (US$ Million)
Europe Glucose Monitoring Devices Market Segmentation
The Europe glucose monitoring devices market is segmented into type, application, testing site, end- user, and country.Based on type, the Europe glucose monitoring devices market is segmented into continuous glucose monitoring devices and self-glucose monitoring devices. The self-glucose monitoring devices segment held a larger share of the Europe glucose monitoring devices market in 2022.
Based on application, the Europe glucose monitoring devices market is segmented into type 1 diabetes and type 2 diabetes. The type 2 diabetes segment held a larger share of the Europe glucose monitoring devices market in 2022.
Based on testing site, the Europe glucose monitoring devices market is segmented into fingertip testing and alternate site testing. The fingertip testing segment held a larger share of the Europe glucose monitoring devices market in 2022.
Based on end user, the Europe glucose monitoring devices market is segmented into healthcare setting and self/homecare. The self/homecare segment held a larger share of the Europe glucose monitoring devices market in 2022.
Based on country, the Europe glucose monitoring devices market is segmented int o the Germany, UK, France, Italy, Spain, and Rest of Europe. Germany dominated the Europe glucose monitoring devices market in 2022.
B. Braun SE, F. Hoffmann-La Roche Ltd, Medtronic Plc, Abbott Laboratories, Ypsomed Holding AG, Senseonics Holdings Inc, Nipro Corp, GE HealthCare Technologies Inc, and Terumo Corp are some of the leading companies operating in the Europe glucose monitoring devices market.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. Europe Glucose Monitoring Devices Market - Key Industry Dynamics
5. Glucose Monitoring Devices Market - Europe Market Analysis
6. Europe Glucose Monitoring Devices Market - Revenue and Forecast to 2030 - by Type
7. Europe Glucose Monitoring Devices Market - Revenue and Forecast to 2030 - by Application
8. Europe Glucose Monitoring Devices Market - Revenue and Forecast to 2030 - by Testing Site
9. Europe Glucose Monitoring Devices Market - Revenue and Forecast to 2030 - by End User
10. Europe Glucose Monitoring Devices Market - Revenue and Forecast to 2030 -Country Analysis
11. Industry Landscape
12. Company Profiles
13. Appendix
List of Tables
List of Figures
Executive Summary
At 11.0% CAGR, the Europe Glucose Monitoring Devices Market is Speculated to be Worth US$ 12,118.27 million by 2030.According to this research, the Europe glucose monitoring devices market was valued at US$ 5,248.87 million in 2022 and is expected to reach US$ 12,118.27 million by 2030, registering a CAGR of 11.0% from 2022 to 2030. Rising incidence of diabetes is a critical factor attributed to the Europe glucose monitoring devices market expansion.
Diabetes among the geriatric population is a growing public health burden worldwide. It is a major cause of morbidity and mortality in the aging population that is later largely attributable to various chronic complications. The aging population is poised to become one of the most significant transformations with a heavy impact on the global social and economic level. This population is growing exponentially worldwide. According to the World Health Organization (2022), by 2030, 1 in 6 people will be aged 60 years or over. The share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. By 2050, the world’s population of people aged 60 years and older will double (2.1 billion). The number of persons aged 80 or older is expected to triple between 2020 and 2050 to reach 426 million. Elderly people are more likely to have diabetes than younger people, and the effect of the disease on quality of life is particularly serious in this population. With the increase in the geriatric population, the prevalence of diabetes has increased. Therefore, there is notable demand for glucose monitoring devices.
On the contrary, high cost of glucose monitoring devices hampers the Europe glucose monitoring devices market.
Based on type, the Europe glucose monitoring devices market is bifurcated into continuous glucose monitoring devices and self-glucose monitoring devices. The self-glucose monitoring devices held 59.6% share of Europe glucose monitoring devices market in 2022, amassing US$ 3,127.04 million. It is projected to garner US$ 6,860.60 million by 2030 to expand at 10.3% CAGR during 2022-2030.
Based on application, the Europe glucose monitoring devices market is bifurcated into type 1 diabetes and type 2 diabetes. The type 2 diabetes segment held 62.0% share of Europe glucose monitoring devices market in 2022, amassing US$ 3,254.97 million. It is projected to garner US$ 7,351.44 million by 2030 to expand at 10.7% CAGR during 2022-2030.
Based on testing site, the Europe glucose monitoring devices market is bifurcated into fingertip testing and alternate site testing. The fingertip testing segment held 70.2% share of Europe glucose monitoring devices market in 2022, amassing US$ 3,682.92 million. It is projected to garner US$ 8,908.13 million by 2030 to expand at 11.7% CAGR during 2022-2030.
Based on end user, the Europe glucose monitoring devices market is bifurcated into healthcare setting and self/homecare. The self/homecare segment held 59.4% share of Europe glucose monitoring devices market in 2022, amassing US$ 3,118.30 million. It is projected to garner US$ 6,986.87 million by 2030 to expand at 10.6% CAGR during 2022-2030.
Based on country, the Europe glucose monitoring devices market has been categorized into the Germany, UK, France, Italy, Spain, and Rest of Europe. Our regional analysis states that Germany captured 29.1% share of Europe glucose monitoring devices market in 2022. It was assessed at US$ 1,526.47 million in 2022 and is likely to hit US$ 3,795.19 million by 2030, exhibiting a CAGR of 12.1% during 2022-2030.
Key players operating the Europe glucose monitoring devices market are B. Braun SE, F. Hoffmann-La Roche Ltd, Medtronic Plc, Abbott Laboratories, Ypsomed Holding AG, Senseonics Holdings Inc, Nipro Corp, GE HealthCare Technologies Inc, and Terumo Corp, among others.
In Dec-2020, LifeScan launched its OneTouch Store, including debut subscription offerings for products and live, unlimited personalized diabetes coaching services accessible through the OneTouch Reveal mobile app. The new store provides people with diabetes a choice from various subscriptions and stand-alone products for home delivery. The store includes a full suite of offerings for consumers, such as with a OneTouch Subscription, consumers get a OneTouch Verio Reflect meter or Verio Flex meter, OneTouch Delica Plus lancing device, 100 OneTouch Delica Plus lancets, and ongoing shipments of 90 test strips per month with 100 lancets every three months, delivered by LifeScan partner, Truepill.
Companies Mentioned
- B. Braun SE
- F. Hoffmann-La Roche Ltd
- Medtronic Plc
- Abbott Laboratories
- Ypsomed Holding AG
- Senseonics Holdings Inc
- Nipro Corp
- GE HealthCare Technologies Inc
- Terumo Corp
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 112 |
| Published | December 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value in 2022 | 5.25 Billion |
| Forecasted Market Value by 2030 | 12.12 Billion |
| Compound Annual Growth Rate | 11.0% |
| Regions Covered | Europe |
| No. of Companies Mentioned | 9 |
